key: cord-0724053-oxal74tf
authors: Generoso, Jaqueline S.; Barichello de Quevedo, João L.; Cattani, Matias; Lodetti, Bruna F.; Sousa, Lucas; Collodel, Allan; Diaz, Alexandre P.; Dal-Pizzol, Felipe
title: Neurobiology of COVID-19: how can the virus affect the brain?
date: 2021-02-10
journal: Braz J Psychiatry
DOI: 10.1590/1516-4446-2020-1488
sha: 24a73cba4862ce6f3ca05e9b7a8e8d19214d872d
doc_id: 724053
cord_uid: oxal74tf

Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19), which has been declared a public health emergency of international interest, with confirmed cases in most countries. COVID-19 presents manifestations that can range from asymptomatic or mild infections up to severe manifestations that lead to hospitalization and death. A growing amount of evidence indicates that the virus may cause neuroinvasion. Postmortem brain study findings have included edema, hemorrhage, hydrocephalus, atrophy, encephalitis, infarcts, swollen axons, myelin loss, gliosis, neuronal satellitosis, hypoxic-ischemic damage, arteriolosclerosis, leptomeningeal inflammation, neuronal loss, and axon degeneration. In addition, the COVID-19 pandemic is causing dangerous effects on the mental health of the world population, some of which can be attributed to its social impact (social distancing, financial issues, and quarantine). There is also a concern that environmental stressors, enhanced by psychological factors, are contributing to the emergence of psychiatric outcomes during the pandemic. Although clinical studies and diagnosing SARS-CoV-2-related neurological disease can be challenging, they are necessary to help define the manifestations and burden of COVID-19 in neurological and psychiatric symptoms during and after the pandemic. This review aims to present the neurobiology of coronavirus and postmortem neuropathological hallmarks.

Emerging pathogens have become significant challenges for public health worldwide. 1 Coronaviruses are enveloped viruses with RNA as genetic material. They are commonly found among humans, other mammals, and birds. In some species, the virus can cause diseases in the respiratory tract, intestinal tract, and liver, as well as neurological disorders in humans. 2 By 2019, two viruses of the coronavirus family had caused major epidemic outbreaks of respiratory diseases: severe acute respiratory syndrome (SARS), from 2002 to 2004, and the Middle East respiratory syndrome (MERS) in 2012. 3 At the end of December 2019, the World Health Organization (WHO) was notified that in Wuhan, China, cases of pneumonia of unknown etiology 4 were occurring and spreading rapidly to other parts of China, Asia, Europe, and later to the Americas. 5 In January 2020, the virus was isolated from airway epithelial cells of patients affected by the disease. The etiologic agent was identified as a new coronavirus; however, it was different from severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). 6 The new virus was named severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) 7 and it causes coronavirus disease 2019 (COVID-19). The COVID-19 pandemic, with confirmed cases in most countries, has been declared a public health emergency of international interest. 8 COVID-19 symptoms range from asymptomatic or mild infections (approximately 80%) to severe signs that lead to hospitalization and death. 9 Transmission occurs from person to person mainly through respiratory droplets, which are usually released when the infected person coughs or sneezes, and direct contact, similar to the human influenza virus, SARS-CoV and MERS-CoV. 8 To a lesser extent, transmission can occur through contaminated surfaces. 10 However, recent evidence supports that transmission can also occur via aerosols, mostly indoors where there is insufficient ventilation and long-term exposure to high concentrations of aerosols. 11, 12 The approximate incubation period from exposure to symptom onset is 4 to 6 days, 12, 13 and 97.5% of symptomatic patients have symptoms within 11 days of infection. 12 The most frequent clinical symptoms are fever, dry cough, fatigue, dyspnea, anosmia, ageusia, gastrointestinal symptoms, or some combination of these. 14 Shortness of breath usually occurs between 5 to 8 days after the first symptoms and is suggestive of disease worsening. 14, 15 Risk factors for COVID-19 complications include old age (4 65 years), cardiovascular disease, chronic lung disease, hypertension, diabetes, obesity, 16 and autoimmune diseases (rheumatoid arthritis, lupus, or psoriasis). 17 By December 2020, more than 67.2 million cases had been confirmed worldwide, resulting in more than 1.5 million deaths. 18 According to the WHO report, more than 26.2 million cases and 720,228 deaths have been confirmed in the Americas; in Europe, there have been more than 18.4 million cases and 412,362 deaths; in Southeast Asia, there have been more than 10.7 million cases and 163,454 deaths; in the Mediterranean there have been more than 4.04 million cases and 102,160 deaths; in Africa there have been over 1.4 million cases and 33,512 deaths; and in the Western Pacific there have been over 800,000 cases and 17,261 deaths. 19 This review aims to present the neurobiology of the coronavirus and its postmortem neuropathological hallmarks.

The coronavirus: severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2)

Although scientists have developed precise techniques and have quickly identified the new coronavirus, it is necessary to investigate its viral structure, colonization and pathogenic mechanisms, and the future consequences of infection on survivors. 20 SARS-CoV-2 is a spherical b-coronavirus that received this name due to its high similarity to SARS-CoV (79.5%). Since they belong to the same family, Coronaviridae, they share several similarities. 21 SARS-CoV-2 is an enveloped virus with a single-stranded positive RNA genome of approximately 30 kb, with a receptor-binding domain (RBD) structure similar to that of SARS-CoV. 22 Open reading frames (ORFs) ORF1a and ORF1b have also been identified in its sequencing, which encode a variety of structural and non-structural proteins that play an essential role in viral survival and virulence power. 23 The four structural proteins encoded by ORFs include spike (S) proteins, membrane (M) proteins, nucleocapsid (N) proteins, and envelope (E) proteins, 24 which are all necessary to produce a structurally complete viral particle 25 (Figure 1) .

Protein S is a highly immunogenic homotrimeric glycoprotein (ranging from 9 to 12 nm) in the outer portion of the virus, which gives the appearance of a solar corona. 26 It is one of the main targets of neutralizing antibodies after host infection and therapeutic and vaccine focus. 27 This protein is essential for virus fixation on the surface of host cells, where the RBD of protein S mediates the interaction with angiotensin-converting enzyme 2 (ACE2). 28 There are two functional subunits of this protein: the S1 subunit, which is responsible for binding to the host cell's receptor, and the S2 subunit, which is responsible for fusion between the viral and cellular membranes, facilitating viral entry into the cell. 27 Protein S can access the endoplasmic reticulum using an N-terminal signal sequence, and it is strongly associated with glycosylated N. 29 Another essential component of SARS-CoV-2 is protein M. This approximately 25-30 kDa protein is the most abundant in the virus, can bind to all other structural proteins, and is responsible for defining the shape of the viral envelope. 30 The interaction between M and N proteins can stabilize and form nucleocapsids, promoting completion of viral assembly. 31 Protein M exists as a dimer and can have two conformations: M LONG, which is associated with rigidity, spike clusters and the curvature of the membrane, and M COMPACT, which is associated with flexibility and low spike density. 32 In addition, the interaction between M and S is essential for the fixation of S in the endoplasmic reticulum -Golgi intermediate compartment/Golgi complex and its incorporation into new virions. 33 The N protein, another structural protein of the virus, consists of two domains: an N-terminal domain and a C-terminal domain. 31 This protein is closely linked to the genetic material forming the nucleocapsid. It is thus involved in processes related to the viral genome, such as RNA transcription and replication, and the response of host cells to viral infections. 34, 35 It is also involved in assembly and viral budding, resulting in the complete formation of the virion. 36 Protein N is still intensely phosphorylated and can generate structural changes, increasing affinity for viral RNA. 33 The last and smallest structural component is protein E (8 to 12 kDa), which has a role in viral production and maturation. 37 This membrane protein has ion channel activity with an N-terminal ectodomain and a C-terminal endodomain. 36 Proteins E, M, and S are incorporated into the lipid envelope of the virion. While protein S is involved in fusion with host membranes and protein M in envelope formation and budding, protein E is not essential for virus replication. However, if it is absent, it can result in virus attenuation and prejudice viral maturation. 38 The mechanism of pathogenicity Many aspects of the pathogenesis of COVID-19 must be understood. Fundamental processes in the life cycle of SARS-CoV-2 in the host include binding, penetration, biosynthesis, maturation, and release. Upon invasion, the virus binds to the host's receptors (binding) and enters cells through endocytosis or membrane fusion (penetration). Afterward, the viral content is released, and the viral RNA enters the cell's nucleus for replication. The viral mRNA is soon copied and used for the production of viral proteins (biosynthesis), and new viruses are organized (maturation) and released. 39 Reports of devastating damage to the cardiovascular system, intestines, kidneys, and brain in COVID-19 patients have surfaced more frequently. 40 Blood coagulation can constrict the vessels, resulting in pulmonary embolism, ischemic stroke, or ischemia in the extremities. 40, 41 The host cell infection mechanism of SARS-CoV-2 is similar to that of SARS-CoV; it is mediated mainly by the ACE2 cell surface receptor 42 and less frequently by CD147. 23 ACE2 is a glycoprotein expressed in the epithelium of the airways, lungs parenchyma, vascular endothelium, heart, kidneys, and small intestine. 43 However, ACE2 receptors are also expressed in regions of the human brain, such as the motor cortex and posterior cingulate, nigra substance, ventricles, middle temporal gyrus, olfactory bulb, ventrolateral medulla, solitary tract nucleus, and vagus nerve. Some central nervous system (CNS) cells, including neurons, microglia, astrocytes, and oligodendrocytes, can also express ACE2. 43, 44 SARS-CoV-2 can access the CNS can occur in two ways: hematogenous dissemination or the neural pathway. 45 Hematogenous dissemination occurs through leukocytes, which serve as a dissemination vehicle for the CNS through the blood-brain barrier (BBB) or bloodcerebrospinal fluid barrier. 46 Access to the CNS can occur by expressing ACE2 in vascular endothelial cells 44 or by infected leukocytes that cross the BBB, which is known as a Trojan horse mechanism. 46 The intense inflammatory response of COVID-19 can lead to increased permeability of the BBB, allowing infected cells, cytokines, and even the virus to pass into the CNS. 47 Neural access involves transporting the virus through the nasal cavity and rhinopharynx through the olfactory and trigeminal nerves, while the lower respiratory tract is accessed through the vagus nerve. 48 The virus then spreads via transsynaptic transfer using endocytosis/exocytosis and the vesicle's fast axonal transport mechanism to move along microtubules to neuronal cell bodies 44 (Figure 2 ).

To enter cells, SARS-CoV-2 uses protein S to bind to the ACE2 receptor via the RBD of the S1 subunit. 20 Therefore, viral internalization is facilitated by type 2 transmembrane serine protease (TMPRSS2), which cleaves ACE2 and the S1/S2 subunit site and allows the fusion of the viral and cellular membranes, a process carried out by the S2 subunit. 49 The virus enters the host cell by endocytosis, releases its genetic material and uses its machinery to translate and replicate RNA and release new viruses 42 ( Figure 3 ).

The host's immune system can detect SARS-CoV-2 through viral RNA, glycoproteins, and other virus molecules, also known as pathogen-associated molecular patterns. 50 These patterns are recognized by pattern recognition receptors, such as Toll-like receptors, which are present in antigen-presenting cells, such as macrophages and monocytes. 51 Protein S can be recognized by TLR4 52 and, after recognition, intracellular signaling begins through signal transmission from the cytoplasmic domain of the TLR to interleukin-1 receptor-associated with kinase 4 (IRAK-4). 53 IRAK-4 activation is mediated by myeloid differentiation protein 88. IRAK-4 stimulates tumor necrosis factor receptor-associated factor 6, and this cascade results in the release of the nuclear transcription factor-kappa B and the mitogen-activated protein kinase pathway, which activates gene expression of proinflammatory molecules, such as tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1b, IL-6, IL-8, IL-33, interferon (IFN)-a, IFN-g, and chemokines. 30 During viral replication, endosomal receptors TLR3 and TLR7 can also recognize viral RNA, resulting in nuclear activation and translocation of interferon regulatory factor-3 and nuclear transcription factor-kappa B, which induces the production of type I IFN (IFN-a) and proinflammatory cytokines. 54 After release, IFN-a can bind to IFN-a/b receptor, activate the Janus kinase pathway and the signal transducer and activator of transcription (STAT), STAT1 and STAT2, which form complexes with interferon regulatory factor-9, initiating the transcription of IFN-stimulated genes. Together, the expression of cytokines, IFNs, and IFN-stimulated genes establish an innate immune response that prevents viral replication in infected cells 54, 55 (Figure 3 ). However, the coronavirus has developed strategies to survive in host cells, including the formation of vesicles that prevent recognition by pattern recognition receptors and the use of structural and non-structural proteins that can suppress the activation of IFNs, which are closely associated with disease severity. 56 Post-mortem brain studies Autopsy tissue samples are essential to understanding the effect and consequences of COVID-19 on the brain. Here we report the results of autopsies of brain samples from patients who died of COVID-19. The following areas of the brain were studied in the reviewed papers: the frontal and occipital lobes, olfactory bulb, cingulate gyrus, corpus callosum, hippocampus, basal ganglia, thalamus, cerebellum, midbrain, pons, medulla, neocortex, brainstem, gyrus rectus, cerebral and cerebellar white and grey matter, and the lateral ventricles. Macroscopically, the studies revealed the presence of edema, 57-59 hemorrhagic lesions, 57-62 hydrocephalus, 63 atrophy, 64 low brain weight, 65 encephalitis, 66 asymmetry in the olfactory bulb, 58 and infarcts. 67, 68 Microscopically, the results included positive astrocyte reactivity evaluated for GFAP, swollen axons 57 and loss of myelin, 57,62 gliosis and neuronal satellitosis, 69 hypoxic-ischemic damage, 67,68,70 mild or moderate arteriolosclerosis, leptomeningeal inflammation, microglial nodules, 67 neuron loss, 66,71 axon degeneration, 62,66 diffuse or focal spongiosis, vascular congestion, and focal ischemic necrosis. 59 For more details about the post-mortem brain studies, see Table 1 .

As the SARS-CoV-2 pandemic progresses, a growing body of evidence indicates that the virus can cause neuroinvasion and affect the CNS in several ways. 79, 80 The virus can gain access to the CNS via the neural pathway (olfactory nerve and nasal cavity) or the hematogenous pathway (infected leukocytes and endothelial cells from the BBB). 44, 45 Neurotropism is also a common feature of the SARS-CoV and MERS-CoV viruses, and it has been reported that the endothelium, glial cells, and neurons express ACE2, which makes them a potential target for SARS-CoV-2. 81 Neurological manifestations during COVID-19 infection can be caused directly by the virus in the CNS or by the host's immune response and systemic complications. 79 After gaining access to the CNS, the virus can cause immune cell infiltration and activate inflammatory pathways through the secretion of cytokines and chemokines and activate thrombotic pathways, which contribute to tissue damage and cause microangiopathy, respectively. 79, 82 Nonspecific symptoms include headache, dizziness, anosmia, ageusia, hypoplasia, and neuralgia (the latter four involving cranial nerves), 47 in addition to sleep disorders, stroke, impaired consciousness, coma, Figure 2 Mechanisms of central nervous system entry. Access to the central nervous system (CNS) through the blood-brain barrier (BBB) can occur by expressing angiotensin-converting enzyme 2 (ACE2) in vascular endothelial cells or by infected leukocytes that cross through the BBB, known as a Trojan horse mechanism (hematogenous pathway). Neural access involves transporting the virus through the nasal cavity and rhinopharynx through the olfactory and trigeminal nerves and the lower respiratory tract through the vagus nerve (neural pathway). CSF = cerebrospinal fluid; MDD = major depressive disorder; SARS-CoV-2 = severe acute respiratory syndrome-related coronavirus-2. seizure, and encephalopathy. 8, 44, 83 Severe COVID-19 patients may have marked vascular dysfunction, which is seen in high levels of D-dimer and procoagulant factors. Thus, thromboembolic complications, including stroke, are commonly seen in these patients. 84 The occurrence of stroke in COVID-19 patients has been reported in some studies. 47, 85 During SARS-CoV-2 infection, coagulopathy and inflammation can cause thrombosis in cerebral blood vessels and cardiac embolism, leading to ischemic stroke. The presence of pre-existing comorbidities, including advanced age, cardiovascular diseases, and cerebral microvascular dysfunction can be a significant risk factor for stroke in COVID-19 patients. 86 Reports of meningoencephalitis 87 and intracerebral hemorrhage in affected patients 88 also indicate that the CNS is invaded by SARS-CoV-2.

Mao et al. 47 were the first to report neurological injury in COVID-19 patients. This study included 214 patients from Wuhan, China, who were hospitalized and tested positive for SARS-CoV-2 infection. The neurological alterations were divided into manifestations of the CNS, peripheral nervous system, and skeletal muscle injury. A total of 78 patients (36.4%) had neurological manifestations, of which 53 (24.8%) were in the CNS, most often including dizziness (36 [16.8%] ) and headache (28 [13.1%] ). There were peripheral nervous system manifestations in (6) How can the COVID-19 affect the brain? (6) How can the COVID-19 affect the brain? (6) How can the COVID-19 affect the brain?

19 (8.9%), including ageusia (12 [5.6%]) and anosmia (11 [5. 1%]). Twenty-three patients (10.7%) had a skeletal muscle injury. Neurological manifestations were also more common in patients with severe infections and included acute cerebrovascular disease, impaired consciousness, and skeletal muscle injury, in addition to a more intense inflammatory response, lymphopenia, and increased levels of C-reactive protein. 47 In another study with 60 patients affected by COVID-19, 41 (68.33%) had neurological symptoms, including mood oscillation in 41.67%, fatigue in 26.67%, headache in 25%, altered vision in 21.67%, myalgia in 15%, reduced mobility in 11.67%, memory loss in 13.33%, ageusia in 6.67%, numbness in 6.67%, tremors in 6.67%, anosmia in 3.33%, and hearing loss in 1.67%. Three months after recovery, more than 50% of the patients still had neurological symptoms. 89 Encephalitis, micro-hemorrhage, hemorrhage, encephalopathy, and cerebral venous embolism have also been reported as consequences of COVID-19 infection. 87 92 A French study of 58 patients found that 40 (69%) were agitated after sedation was discontinued, and confusion was observed in 26 (65%) in the intensive care unit according to the Confusion Assessment Method. Some patients also had larger leptomeningeal spaces (13.62%), and bilateral frontotemporal hypoperfusion was observed in eight patients. Two asymptomatic patients had small acute ischemic strokes, and one patient had a subacute ischemic stroke. Forty-five patients were evaluated after hospital discharge and 15 (33%) showed inattention, disorientation or poorly organized movements in response to the command. 93

Several studies have addressed the impact of COVID-19 on mental health. Psychiatric manifestations can arise due to the direct effects of the virus entering the CNS or to the indirect effects of immune response, 94 as well as to additional social stressors, which can contribute to the incidence and exacerbation of psychiatric disorders. 95 Preclinical studies have shown an association between depressive-like behavior and high levels of tumor necrosis factor-alpha in the brain in an experimental model of pneumococcal meningitis. 96, 97 Persistent inflammatory response and behavioral deficits have been observed in adult offspring of female rats submitted to maternal immune activation, which suggests that inflammation could increase the risk of psychiatric disorders. 98 In fact, previous studies support that immune response participates in the pathophysiology of mental illnesses such as depression, bipolar disorders, [99] [100] [101] and suicidal behavior. 102, 103 Specifically regarding COVID-19, Ruan et al. 104 showed that patients affected by the virus have high levels of inflammatory markers, which were predictors of mortality due to the disease. A potential link between inflammation due to COVID-19 and psychiatric manifestations has also been demonstrated in the literature. Gouse et al. 105 and about 30 days after hospital treatment (psychiatric assessment). It was found that more than half of the patients presented psychiatric symptoms in the pathological range of at least one psychopathological dimension. Moreover, the baseline systemic immune-inflammation index (platelets  neutrophils/lymphocytes) was positively associated with depression and anxiety scores. 106 A similar finding was reported by Hu et al., 107 in which patients with COVID-19 presented a high frequency of depressive (45.9%), anxiety (38.8%), and insomnia (54.1%) symptoms, which were positively and significantly associated with higher levels of IL-1b. The social stressors associated with the pandemic, including physical distancing as a mechanism to prevent its spread, financial issues, and the quarantine itself, can lead to an additional risk of psychiatric disorders. 108 Biological, psychological, and sociocultural factors could also interact to determine the impact of the COVID-19 on mental health. 109 A representative panel survey published by the Center for Surveillance, Epidemiology, and Laboratory Services of the U.S. Centers for Disease Control and Prevention reported an increase in the prevalence of anxiety disorder (approximately three times), depressive disorder (approximately four times), and suicidal ideation (approximately two times) during June 24-30, 2020 compared to previous years (2018 or 2019). 110 Regarding the latter, the findings were remarkable among young adults (18-34 years old) and those who had not completed high school, with 25.5 and 30%, respectively, reporting that had seriously considered suicide in the past 30 days. 110 Krishnamoorthy et al. 111 reviewed the prevalence of mental disorders, psychiatric symptoms, and mental distress among COVID-19 patients, healthcare workers, and the general population during the COVID-19 pandemic. The pooled effect size for patients with COVID-19 was larger than that of healthcare workers or the general population for depression (42, 25 , and 24%, respectively), anxiety (37, 24 , and 26%, respectively), post-traumatic stress symptoms (96, 13 , and 15%, respectively), and poor sleep quality (82, 43 , and 34%, respectively). 111 Considering 12-month mood disorder and anxiety prevalences of 9.5 and 18.1%, respectively, from a 2001-2003 U.S. survey, the rates reported by Krishnamoorthy et al. during the COVID-19 pandemic 111 are substantial. 112 The apparent higher risk of psychiatric disorders among patients with COVID-19 raises concerns about the safety of available treatments, especially pharmacological treatments. An international, multi-disciplinary working group of experts published evidence-based recommendations for the appropriate management of psychotropics in patients with COVID-19. 113 It recommended special care regarding the potential interaction between COVID-19 treatments and psychotropic medications, the risk of respiratory depression, cardiovascular effects, and thromboembolism, in addition evaluating the dosage of patients currently in treatment. 113 Clinicians should also consider evidencebased telehealth psychotherapeutic and psychoeducation interventions due to their efficacy and feasibility. 114, 115 In an editorial, da Silva et al. 95, 116 identified some mental health topics worthy of attention, including inadequate access to health services, especially in developing countries. A recent retrospective cohort study by Williams et al. 117 showed that between March 1 and May 31, 2020, the first diagnosis of psychiatric problems was 50% lower than expected based on previous years, which suggests considerable underdiagnosis. The authors warned of a potential overload in the mental health system due to reduced access during the pandemic.

Longitudinal studies are necessary to evaluate the biological and environmental risk factors, as well as the protective interventions, that have shaped the impact of COVID-19 on mental health. Regarding protective factors, institutional support and resilience were found as mediators of the relationship between COVID-19-related stressors and psychological distress, which suggests the potential benefits of interventions that address both during a public health emergency. 118 In a study of medical workers during the COVID-19 outbreak, resilience was negatively correlated with depression and anxiety and was positively correlated with active coping styles. 119 Some programs have been implemented to build resilience, such as the Mount Sinai Center for Stress, Resilience, and Personal Growth, 120 the Psychological Resilience Model, 121 and CopeColumbia. 122 Some of these initiatives include principles from psychotherapeutic interventions, such as cognitive-behavioral and acceptance and commitment therapies. Interestingly, a systematic review on the association between psychological interventions and immune system function found decreased proinflammatory cytokines and increased immune cell counts over time following treatment, especially for cognitive behavior therapy and multiple or combined psychosocial interventions. 123 Moutier 124 argues that this is a moment when evidence-based strategies for suicide prevention should be prioritized and maximized in the public health agenda at the community and federal levels. Despite the severe consequences associated with the pandemic, the knowledge acquired during this period can provide positive lessons for the field of mental health, both in terms of primary prevention and intervention. 125 

In conclusion, it must be pointed out that with the increasing number SARS-CoV-2 infections and the pandemic's potentially long-lasting social stressors, many patients will have neurological and psychiatric manifestations that could result in a considerable burden for these individuals, their families, and society. Psychiatric symptoms will not be limited only to patients affected by COVID-19, since environmental stressors are highly associated with the etiology and pathophysiology of psychiatric disorders. 126, 127 Although clinical and epidemiological studies and diagnosing brain disease associated with SARS-CoV-2 can be challenging, they are necessary to help define the COVID-19 burden during and after the pandemic.

A''IV to ''Z''IKV: attacks from emerging and reemerging pathogens

Coronavirus pathogenesis

Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a crosssectional analysis

Pneumonia of unknown cause --China

A review of pathophysiology and neuropsychiatric manifestations of COVID-19

A novel coronavirus from patients with pneumonia in China

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Clinical characteristics of coronavirus disease 2019 in China

SARS-CoV-2 seroprevalence in COVID-19 hotspots

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Aerosol transmission of SARS-CoV-2? Evidence, prevention and control

Mild or moderate covid-19

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Factors associated with COVID-19-related death using OpenSAFELY

Coronavirus disease (COVID-19) -weekly epidemiological update

Origin and evolution of pathogenic coronaviruses

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

The architecture of SARS-CoV-2 transcriptome

Overview of lethal human coronaviruses

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses

Ultrastructural characterization of SARS coronavirus

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Architecture of the SARS coronavirus prefusion spike

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response

Modular organization of SARS coronavirus nucleocapsid protein

Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control

Coronaviruses: an overview of their replication and pathogenesis

Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Properties of coronavirus and SARS-CoV-2

Coronavirus envelope protein: current knowledge

Structure and inhibition of the SARS coronavirus envelope protein ion channel

COVID-19 pathophysiology: a review

How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes

Large-vessel stroke as a presenting feature of covid-19 in the young

Immune-mediated approaches against COVID-19

Angiotensin-converting enzyme 2 in the brain: properties and future directions

Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review

Targetable biological mechanisms implicated in emergent psychiatric conditions associated with SARS-CoV-2 infection

Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses

Neurologic manifestations of hospitalized patients with coronavirus disease

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Pathogen recognition and innate immunity

Pathogenesis and pathophysiology of pneumococcal meningitis

Coronavirus infections and immune responses

The immunopathogenesis of sepsis

SARS and MERS: recent insights into emerging coronaviruses

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic

Molecular immune pathogenesis and diagnosis of COVID-19

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Early postmortem brain MRI findings in COVID-19 non-survivors

Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Cerebral microvascular injury in severe COVID-19. medRxiv

COVID-19: postmortem diagnostic and biosafety considerations

Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series

Autopsy findings and venous thromboembolism in patients with COVID-19

Early evidence of pronounced brain involvement in fatal COVID-19 outcomes

Neuropathological features of Covid-19

Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19

Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Neuropathological features of Covid-19

COVID-19 autopsies

First ultrastructural autoptic findings of SARS -Cov-2 in olfactory pathways and brainstem

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Multiorgan and renal tropism of SARS-CoV-2

Postmortem examination of patients with COVID-19

Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Arch

Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation

Neurological associations of COVID-19

A call for a global COVID-19 Neuro Research Coalition

Neurologic manifestations in hospitalized patients with COVID-19: the ALBA-COVID registry

Endothelial cell infection and endotheliitis in COVID-19

Spectrum of neuropsychiatric manifestations in COVID-19

Characteristics of ischaemic stroke associated with COVID-19

How can the COVID-19 affect the brain?

SARS-CoV-2 and stroke in a New York healthcare system

Case 26-2020: a 60-year-old woman with altered mental status and weakness on the left side

SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis

COVID-19 and intracerebral haemorrhage: causative or coincidental?

Cerebral microstructural changes in COVID-19 patients --an MRI-based 3-month follow-up study

Updates on what ACS reported: emerging evidences of COVID-19 with nervous system involvement

Clinical characteristics of 82 death cases with COVID-19

Neurologic and radiographic findings associated with COVID-19 infection in children

Neurologic features in severe SARS-CoV-2 infection

Mental health and the Covid-19 pandemic

Mental health: why it still matters in the midst of a pandemic

Depression-like adult behaviors may be a longterm result of experimental pneumococcal meningitis in wistar rats infants

Imipramine reverses depressive-like parameters in pneumococcal meningitis survivor rats

Maternal immune activation induced by lipopolysaccharide triggers immune response in pregnant mother and fetus, and induces behavioral impairment in adult rats

A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients

Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials

Adverse childhood experiences and depressive symptoms in later life: longitudinal mediation effects of inflammation

Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients

Blunted HPA axis activity prior to suicide attempt and increased inflammation in attempters

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism

Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors

Factors related to mental health of inpatients with COVID-19 in Wuhan

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Obsessive-compulsive disorder during the COVID-19 pandemic

Mental health, substance use, and suicidal ideation during the COVID-19 pandemic -United States

Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: a systematic review and meta-analysis

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations

Psychological therapies and psychoeducational recommendations for bipolar disorder treatment during COVID-19 pandemic

Telepsychiatry and the Coronavirus disease 2019 pandemic-current and future outcomes of the rapid virtualization of psychiatric care

Comment on ''Mental health: why it still matters in the midst of a pandemic

Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study

Psychological distress among hiv healthcare providers during the COVID-19 pandemic in China: mediating roles of institutional support and resilience

Factors associated with resilience among non-local medical workers sent to Wuhan, China during the COVID-19 outbreak

Mount Sinai's Center for Stress, Resilience and Personal Growth as a model for responding to the impact of COVID-19 on health care workers

The development of the 'COVID-19 Psychological Resilience Model' and its efficacy during the COVID-19 pandemic in China

Supporting the well-being of health care providers during the COVID-19 pandemic: the CopeColumbia response

Psychosocial interventions and immune system function: a systematic review and meta-analysis of randomized clinical trials

Suicide prevention in the COVID-19 era: transforming threat into opportunity

How mental health care should change as a consequence of the COVID-19 pandemic

Gene-environment interactions in mental disorders

Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness

The authors would like to thank Universidade do Extremo Sul Catarinense (UNESC), Conselho Nacional de Desenvolvimento Científico e Tecnoló gico (CNPq), and Fun-dac¸ã o de Amparo à Pesquisa e Inovac¸ã o de Santa Catarina (FAPESC). APD is supported by the Brain & Behavior Research Foundation (NARSAD) Young Investigator Grant.

The authors report no conflicts of interest.